{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:27:57Z","timestamp":1789032477016,"version":"build-2803163510"},"reference-count":37,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with the use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) and subsequent maintenance therapies in eligible newly diagnosed patients. However, clinical trials using auto-HSCT followed by lenalidomide maintenance have shown an increased risk of second primary malignancies (SPM), including second hematological malignancies (SHM). We evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in patients with MM after auto-HSCT using CIBMTR registry data. Adult patients with MM who underwent first auto-HSCT in the United States with melphalan conditioning regimen from 2011 to 2018 and received maintenance therapy were included (n\u00a0= 3948). At a median follow-up of 37\u00a0months, 175 (4%) patients developed SPM, including 112 (64%) solid, 36 (20%) myeloid, 24 (14%) SHM, not otherwise specified, and 3 (2%) lymphoid malignancies. Multivariate analysis demonstrated that SPM and SHM were associated with an inferior PFS (hazard ratio [HR] 2.62, P\u00a0&amp;lt; .001 and HR 5.01, P\u00a0&amp;lt; .001, respectively) and OS (HR 3.85, P\u00a0&amp;lt; .001 and HR 8.13, P\u00a0&amp;lt; .001, respectively). In patients who developed SPM and SHM, MM remained the most frequent primary cause of death (42% vs 30% and 53% vs 18%, respectively). We conclude the development of SPM and SHM leads to a poor survival in patients with MM and is an important survivorship challenge. Given the median survival for MM continues to improve, continued vigilance is needed to assess the risks of SPM and SHM with maintenance therapy post\u2013auto-HSCT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009138","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T22:07:02Z","timestamp":1677276422000},"page":"2746-2757","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Impact of second primary malignancy post\u2013autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2460-0698","authenticated-orcid":false,"given":"Brittany Knick","family":"Ragon","sequence":"first","affiliation":[{"name":"1Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-336X","authenticated-orcid":false,"given":"Mithun Vinod","family":"Shah","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"3CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Estrada-Merly","sequence":"additional","affiliation":[{"name":"3CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lohith","family":"Gowda","sequence":"additional","affiliation":[{"name":"4Yale Cancer Center and Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemlyn","family":"George","sequence":"additional","affiliation":[{"name":"5University of Colorado School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-4522","authenticated-orcid":false,"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[{"name":"6The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-7927","authenticated-orcid":false,"given":"Shahrukh","family":"Hashmi","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Mayo Clinic, Rochester, MN"},{"name":"8Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"9Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-891X","authenticated-orcid":false,"given":"Navneet S.","family":"Majhail","sequence":"additional","affiliation":[{"name":"10Sarah Cannon, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[{"name":"11Division of Medical Oncology, University of Washington, Seattle, WA"},{"name":"12Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0003-0130","authenticated-orcid":false,"given":"Ayman","family":"Saad","sequence":"additional","affiliation":[{"name":"13Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard C.","family":"Hildebrandt","sequence":"additional","affiliation":[{"name":"14Ellis Fischel Cancer Center, University of Missouri, Columbia, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Mian","sequence":"additional","affiliation":[{"name":"15McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Bilal","family":"Abid","sequence":"additional","affiliation":[{"name":"16Divisions of Hematology\/Oncology & Infectious Diseases, BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoo","family":"Battiwalla","sequence":"additional","affiliation":[{"name":"17Sarah Cannon Blood Cancer Network, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros J.","family":"Lekakis","sequence":"additional","affiliation":[{"name":"18Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-3615","authenticated-orcid":false,"given":"Sagar S.","family":"Patel","sequence":"additional","affiliation":[{"name":"19Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant S.","family":"Murthy","sequence":"additional","affiliation":[{"name":"9Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6034-8939","authenticated-orcid":false,"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[{"name":"20Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Strouse","sequence":"additional","affiliation":[{"name":"21Division of Hematology, Oncology, and Bone & Marrow Transplantation, University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4739-265X","authenticated-orcid":false,"given":"Sherif M.","family":"Badawy","sequence":"additional","affiliation":[{"name":"22Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL"},{"name":"23Division of Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[{"name":"24University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"25Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[{"name":"26Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[{"name":"27John Theurer Cancer Center at Hackensack Meridian School of Medicine, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy H.","family":"Lee","sequence":"additional","affiliation":[{"name":"28Royal Adelaide Hospital, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaphol","family":"Pawarode","sequence":"additional","affiliation":[{"name":"29Adult Blood and Marrow Transplantation and Cellular Therapy, Rogel Cancer Center, Division of Hematology\/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[{"name":"30Department of Medical Oncology, Division of Hematological Malignancies, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-5570","authenticated-orcid":false,"given":"Kevin C.","family":"Miller","sequence":"additional","affiliation":[{"name":"31Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona A.","family":"Holmberg","sequence":"additional","affiliation":[{"name":"12Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[{"name":"32Myeloma, Waldenstrom's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[{"name":"33The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pashna N.","family":"Munshi","sequence":"additional","affiliation":[{"name":"34Stem Cell Transplant and Cellular Immunotherapy Program, MedStar Georgetown University Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"35Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"},{"name":"36Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr.","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"32Myeloma, Waldenstrom's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldeep","family":"Wirk","sequence":"additional","affiliation":[{"name":"37Bone Marrow Transplant Program, Penn State Cancer Institute, Hershey, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2510-6536","authenticated-orcid":false,"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[{"name":"32Myeloma, Waldenstrom's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar H.","family":"Qazilbash","sequence":"additional","affiliation":[{"name":"20Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Shah","sequence":"additional","affiliation":[{"name":"38Haematology Research & Development, AstraZeneca, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"39Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"19","key":"2023062613533979200_bib1","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023062613533979200_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"2023062613533979200_bib3","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1200\/EDBK_238527","article-title":"Induction therapy for newly diagnosed multiple myeloma","volume":"39","author":"Paul","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"12","key":"2023062613533979200_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma--an IMWG Research Project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J"},{"issue":"17","key":"2023062613533979200_bib5","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2023062613533979200_bib6","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1200\/JCO.21.02372","article-title":"Trends in late mortality and life expectancy after autologous blood or marrow transplantation over three decades: a BMTSS report","volume":"40","author":"Bhatia","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"2023062613533979200_bib7","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1182\/blood-2012-11-466961","article-title":"Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2023062613533979200_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/jnci\/djy073","article-title":"Association between autologous stem cell transplant and survival among californians with multiple myeloma","volume":"111","author":"Rosenberg","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"23","key":"2023062613533979200_bib9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V126.23.391.391","article-title":"Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the intergroupe francophone du myelome (IFM\/DFCI 2009 Trial)","volume":"126","author":"Attal","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2023062613533979200_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/ejh.13650","article-title":"Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma","volume":"107","author":"Jonsdottir","year":"2021","journal-title":"Eur J Haematol"},{"key":"2023062613533979200_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk Res"},{"issue":"4","key":"2023062613533979200_bib12","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.bbmt.2014.12.028","article-title":"New cancers after autotransplantations for multiple myeloma","volume":"21","author":"Mahindra","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"2023062613533979200_bib13","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2023062613533979200_bib14","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"29","key":"2023062613533979200_bib15","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023062613533979200_bib16","first-page":"436","article-title":"Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the myeloma XI trial","volume":"130","author":"Jackson","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2023062613533979200_bib17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"issue":"12","key":"2023062613533979200_bib18","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","article-title":"A\u00a0review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide","volume":"119","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2023062613533979200_bib19","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1038\/bcj.2016.114","article-title":"Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial","volume":"6","author":"Jones","year":"2016","journal-title":"Blood Cancer J"},{"issue":"12","key":"2023062613533979200_bib20","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.1016\/S2352-3026(22)00289-7","article-title":"Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Saleem","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"2023062613533979200_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023062613533979200_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-021-00454-y","article-title":"Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma","volume":"11","author":"Nadiminti","year":"2021","journal-title":"Blood Cancer J"},{"issue":"16","key":"2023062613533979200_bib23","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/blood-2017-09-805879","article-title":"Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT","volume":"131","author":"Berger","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2023062613533979200_bib24","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3109\/10428194.2014.970543","article-title":"Therapy-related myelodysplastic syndrome\/acute leukemia after multiple myeloma in the era of novel agents","volume":"56","author":"Gertz","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2023062613533979200_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"2023062613533979200_bib26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/bjh.15426","article-title":"Second primary malignancy after multiple myeloma-population trends and cause-specific mortality","volume":"182","author":"Costa","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"2023062613533979200_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-020-00400-4","article-title":"Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients","volume":"11","author":"Rosenberg","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2023062613533979200_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"2023062613533979200_bib29","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.3324\/haematol.2015.134049","article-title":"Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study","volume":"101","author":"Jonsdottir","year":"2016","journal-title":"Haematologica"},{"issue":"15_suppl","key":"2023062613533979200_bib30","doi-asserted-by":"crossref","first-page":"10507","DOI":"10.1200\/JCO.2021.39.15_suppl.10507","article-title":"Second primary malignancies (SPM) in African American (AA) and white patients with multiple myeloma in the National Veterans Affairs (VA) healthcare system","volume":"39","author":"Premji","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023062613533979200_bib31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/ejh.13750","article-title":"Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma","volume":"108","author":"Vasudevan Nampoothiri","year":"2022","journal-title":"Eur J Haematol"},{"issue":"11","key":"2023062613533979200_bib32","doi-asserted-by":"crossref","first-page":"923.e1","DOI":"10.1016\/j.jtct.2021.08.010","article-title":"Allogeneic transplantation to treat therapy-related myelodysplastic syndrome and acute myelogenous leukemia in adults","volume":"27","author":"Metheny","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2023062613533979200_bib33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-022-00680-y","article-title":"Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma","volume":"12","author":"Parrondo","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"2023062613533979200_bib34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41375-018-0213-y","article-title":"Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma","volume":"33","author":"Aldoss","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"2023062613533979200_bib35","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbmt.2018.01.006","article-title":"Incidence of second primary malignancies after autologous transplantation for multiple myeloma in the era of novel agents","volume":"24","author":"Sahebi","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2023062613533979200_bib36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023062613533979200_bib37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2016.09.005","article-title":"National institutes of health hematopoietic cell transplantation late effects initiative: the subsequent neoplasms working group report","volume":"23","author":"Morton","year":"2017","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/12\/2746\/2060111\/blooda_adv-2022-009138-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/12\/2746\/2060111\/blooda_adv-2022-009138-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T13:54:50Z","timestamp":1687787690000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/12\/2746\/494705\/Impact-of-second-primary-malignancy-post"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,6,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009138","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}